Essential thrombocythemia · 3 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ruxolitinib monotherapy Variant #01 | — | R 60 650 | 28d | — | — | — | — | 2 |
Anagrelide monotherapy Variant #01 | — | R 3 030 | 28d | — | — | — | — | — |
Peginterferon alfa-2a monotherapy N/A - secondary systemic drug | — | R 7 | 7d | — | — | — | — | — |
3 of 3 regimens shown